SCHEMBL6132215

SCHEMBL6132215

COC(=O)c1ccc(C(=O)NNC(=O)c2ccc(N3CCN(C4CCC(c5ccccc5)CC4)CC3)cc2)cc1

nearest known ligand 0.58

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 11/20 0.53
ALDH1A1 P00352 8/20 0.53
TRPV6 Q9H1D0 2/20 0.52
KMT2A Q03164 3/20 0.49
MEN1 O00255 2/20 0.49
LMNA P02545 1/20 0.49
TSHR P16473 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.47
RECQL P46063 1/20 0.47
GAA P10253 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
ORAI1 Q96D31 1/20 0.46
NPC1 O15118 2/20 0.45
RAB9A P51151 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6134863 0.85 KMT2A (0.51) KDM4EALDH1A1KMT2AMEN1LMNA
SCHEMBL6134989 0.85 ALDH1A1 (0.51) KDM4EALDH1A1KMT2AMEN1TDP1
SCHEMBL6134631 0.84 HDAC3 (0.50) KDM4EALDH1A1KMT2AMEN1TDP1
SCHEMBL6132502 0.83 KDM4E (0.51) KDM4EALDH1A1TRPV6KMT2AMEN1
SCHEMBL6134612 0.83 ALDH1A1 (0.49) KDM4EALDH1A1KMT2AMEN1TDP1
SCHEMBL6132342 0.83 ALDH1A1 (0.54) KDM4EALDH1A1TRPV6KMT2AMEN1
SCHEMBL6132158 0.81 KDM4E (0.52) KDM4EALDH1A1KMT2AMEN1LMNA
SCHEMBL6132773 0.81 KDM4E (0.52) KDM4EALDH1A1KMT2AMEN1LMNA
SCHEMBL6132159 0.81 KDM4E (0.52) KDM4EALDH1A1KMT2AMEN1LMNA
Hydrochloric Acid SCHEMBL7333163 0.81 KDM4E (0.55) KDM4EALDH1A1TRPV6KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6884774-B2 Cyclic hexapeptide derivatives FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2005-04-26 US disclosed
EP-1259535-B1 CYCLIC HEXAPEPTIDE DERIVATIVES FUJISAWA PHARMACEUTICAL CO (JP) 2005-04-13 EP disclosed
US-20030083238-A1 Cyclic hexapeptide derivatives ASTELLAS PHARMA INC. (JP) 2003-05-01 US disclosed
EP-1259535-A1 CYCLIC HEXAPEPTIDE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-11-27 EP disclosed
WO-2001060846-A1 CYCLIC HEXAPEPTIDE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-08-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030083238-A1 Cyclic hexapeptide derivatives NGLY1, ALG1, CHIT1 KDM4E 4687/4885ALDH1A1 4718/4885TRPV6 4420/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.